Last reviewed · How we verify

Vonoprazan and Amoxicillin

Kaohsiung Medical University · FDA-approved active Small molecule

Vonoprazan and Amoxicillin is a Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) Small molecule drug developed by Kaohsiung Medical University. It is currently FDA-approved for Helicobacter pylori infection eradication (as part of combination therapy).

Vonoprazan inhibits gastric acid secretion by blocking the proton pump, while amoxicillin is a beta-lactam antibiotic that kills Helicobacter pylori bacteria by disrupting cell wall synthesis.

Vonoprazan inhibits gastric acid secretion by blocking the proton pump, while amoxicillin is a beta-lactam antibiotic that kills Helicobacter pylori bacteria by disrupting cell wall synthesis. Used for Helicobacter pylori infection eradication (as part of combination therapy).

At a glance

Generic nameVonoprazan and Amoxicillin
SponsorKaohsiung Medical University
Drug classProton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin)
TargetH+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin)
ModalitySmall molecule
Therapeutic areaGastroenterology / Infectious Disease
PhaseFDA-approved

Mechanism of action

This is a combination therapy for H. pylori eradication. Vonoprazan (a potassium-competitive acid blocker) suppresses gastric acid production, creating an environment where amoxicillin can more effectively penetrate and eliminate H. pylori. Amoxicillin works by inhibiting bacterial cell wall cross-linking, leading to bacterial cell death. Together, they form part of a triple or quadruple therapy regimen for H. pylori infection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vonoprazan and Amoxicillin

What is Vonoprazan and Amoxicillin?

Vonoprazan and Amoxicillin is a Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) drug developed by Kaohsiung Medical University, indicated for Helicobacter pylori infection eradication (as part of combination therapy).

How does Vonoprazan and Amoxicillin work?

Vonoprazan inhibits gastric acid secretion by blocking the proton pump, while amoxicillin is a beta-lactam antibiotic that kills Helicobacter pylori bacteria by disrupting cell wall synthesis.

What is Vonoprazan and Amoxicillin used for?

Vonoprazan and Amoxicillin is indicated for Helicobacter pylori infection eradication (as part of combination therapy).

Who makes Vonoprazan and Amoxicillin?

Vonoprazan and Amoxicillin is developed and marketed by Kaohsiung Medical University (see full Kaohsiung Medical University pipeline at /company/kaohsiung-medical-university).

What drug class is Vonoprazan and Amoxicillin in?

Vonoprazan and Amoxicillin belongs to the Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) class. See all Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) drugs at /class/proton-pump-inhibitor-vonoprazan-beta-lactam-antibiotic-amoxicillin.

What development phase is Vonoprazan and Amoxicillin in?

Vonoprazan and Amoxicillin is FDA-approved (marketed).

What are the side effects of Vonoprazan and Amoxicillin?

Common side effects of Vonoprazan and Amoxicillin include Diarrhea, Nausea, Abdominal discomfort, Headache, Allergic reaction (amoxicillin).

What does Vonoprazan and Amoxicillin target?

Vonoprazan and Amoxicillin targets H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin) and is a Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin).

Related